Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.51 +5.14%

+$0.45 today

Market cap
$53.05M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.00M

Average 0.05M

Income Statement

Follow revenue through to earnings.

Revenue

$43.77M

FY 2025 · Annual

+589.9% YoY

Operating Income

-$41.98M

FY 2025 · Annual

Net Income

-$35.04M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

XLO Earnings Waterfall · TTM

NASDAQ:XLO · Revenue to Net Income

Key Ratios

EPS$-5.65
Gross Margin51.9%
Net Margin-70.3%
P/E Ratio-5.1
P/S Ratio43.5

Analysis

$53.5M of revenue converted into -$31.3M of net income for the selected period. Gross margin is 51.9% and net margin is -70.3%, showing how much revenue survives after costs and taxes. EPS is $-5.65, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 12, 2026
S-8S-8 filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026

How much revenue does XLO generate?

Xilio Therapeutics, Inc. (XLO) reported $43.77M of revenue in fiscal 2025.

Is XLO profitable?

Xilio Therapeutics, Inc. (XLO) reported -$35.04M of net income, with a net margin of -80.1%.